{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:21:07Z","timestamp":1790882467148,"version":"4.1.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.2215\/cjn.06090809","type":"journal-article","created":{"date-parts":[[2009,11,5]],"date-time":"2009-11-05T22:26:37Z","timestamp":1257459997000},"page":"360-364","source":"Crossref","is-referenced-by-count":60,"title":["Biomarkers of Fabry Disease Nephropathy"],"prefix":"10.2215","volume":"5","author":[{"given":"Raphael","family":"Schiffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Waldek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariela","family":"Benigni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Auray-Blais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-32-20230601","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: Progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R2-32-20230601","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1212\/WNL.32.10.1139","article-title":"Fabry disease: Detection of heterozygotes by examination of glycolipids in urinary sediment","volume":"32","author":"Cable","year":"1982","journal-title":"Neurology"},{"key":"R3-32-20230601","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1373\/clinchem.2004.041418","article-title":"Urinary lipid profiling for the identification of Fabry hemizygotes and heterozygotes","volume":"51","author":"Fuller","year":"2005","journal-title":"Clin Chem"},{"key":"R4-32-20230601","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/01.md.0000178976.62537.6b","article-title":"The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: A cross-sectional study of a large cohort of clinically affected heterozygous women","volume":"84","author":"Gupta","year":"2005","journal-title":"Medicine (Baltimore"},{"key":"R5-32-20230601","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease","volume":"97","author":"Schiffmann","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R6-32-20230601","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ymgme.2007.10.001","article-title":"Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease","volume":"93","author":"Auray-Blais","year":"2008","journal-title":"Mol Genet Metab"},{"key":"R7-32-20230601","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00467-008-0846-6","article-title":"Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes","volume":"23","author":"Kitagawa","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"R8-32-20230601","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1542\/peds.2004-1678","article-title":"Pediatric Fabry disease","volume":"115","author":"Ries","year":"2005","journal-title":"Pediatrics"},{"key":"R9-32-20230601","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10545-006-0484-8","article-title":"The Dutch Fabry cohort: Diversity of clinical manifestations and Gb3 levels","volume":"30","author":"Vedder","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"R10-32-20230601","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ymgme.2009.04.009","article-title":"Fabry disease urinary globotriaosylceramide\/creatinine biomarker evaluation by liquid chromatography-tandem mass spectrometry in healthy infants from birth to 6 months","volume":"97","author":"Barr","year":"2009","journal-title":"Mol Genet Metab"},{"key":"R11-32-20230601","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/ajcp\/82.1.24","article-title":"Immunohistochemical localization of glycosphingolipid in urinary renal tubular cells in Fabry's disease","volume":"82","author":"Chatterjee","year":"1984","journal-title":"Am J Clin Pathol"},{"key":"R12-32-20230601","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJM197212142872402","article-title":"Enzyme replacement therapy by renal allotransplantation in Fabry's disease","volume":"287","author":"Clarke","year":"1972","journal-title":"N Engl J Med"},{"key":"R13-32-20230601","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ki.1978.32","article-title":"Early renal changes in hemizygous and heterozygous patients with Fabry's disease","volume":"13","author":"Gubler","year":"1978","journal-title":"Kidney Int"},{"key":"R14-32-20230601","doi-asserted-by":"crossref","first-page":"F230","DOI":"10.1152\/ajprenal.90507.2008","article-title":"Glomerular epithelial cells in the urine: What has to be done to make them worthwhile?","volume":"296","author":"Skoberne","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"R15-32-20230601","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10545-006-0444-3","article-title":"Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease","volume":"30","author":"Auray-Blais","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"R16-32-20230601","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10545-009-1055-6","article-title":"Proposed high-risk screening protocol for Fabry disease in patients with renal and vascular disease","volume":"32","author":"Auray-Blais","year":"2009","journal-title":"J Inherit Metab Dis"},{"key":"R17-32-20230601","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: Safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R18-32-20230601","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"R19-32-20230601","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","article-title":"Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3","volume":"94","author":"Vedder","year":"2008","journal-title":"Mol Genet Metab"},{"key":"R20-32-20230601","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1681\/ASN.2006121400","article-title":"Antiproteinuric therapy and fabry nephropathy: Sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta","volume":"18","author":"Tahir","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R22-32-20230601","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s10545-008-0900-3","article-title":"Abnormal expression and processing of uromodulin in Fabry disease reflects tubular cell storage alteration and is reversible by enzyme replacement therapy","volume":"31","author":"Vylet' al","year":"2008","journal-title":"J Inherit Metab Dis"},{"key":"R23-32-20230601","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1056-8727(97)00045-7","article-title":"Markers of diabetic nephropathy","volume":"12","author":"Hong","year":"1998","journal-title":"J Diabet Complications"},{"key":"R24-32-20230601","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1159\/000046097","article-title":"Urinary podocytes in primary focal segmental glomerulosclerosis","volume":"89","author":"Hara","year":"2001","journal-title":"Nephron"},{"key":"R25-32-20230601","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ajog.2007.02.007","article-title":"Urinary podocyte excretion as a marker for preeclampsia","volume":"196","author":"Garovic","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"R26-32-20230601","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000013302","article-title":"Urinary excretion of podocytes reflects disease activity in children with glomerulonephritis","volume":"18","author":"Hara","year":"1998","journal-title":"Am J Nephrol"},{"key":"R27-32-20230601","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/ndt\/15.9.1379","article-title":"Urinary excretion of podocytes in patients with diabetic nephropathy","volume":"15","author":"Nakamura","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"R28-32-20230601","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1681\/ASN.2007121328","article-title":"Urine podocyte mRNAs mark progression of renal disease","volume":"20","author":"Sato","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R29-32-20230601","doi-asserted-by":"crossref","first-page":"c169","DOI":"10.1159\/000104428","article-title":"Messenger RNA expression of podocyte-associated molecules in the urinary sediment of patients with diabetic nephropathy","volume":"106","author":"Wang","year":"2007","journal-title":"Nephron Clin Pract"},{"key":"R30-32-20230601","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: A randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"R31-32-20230601","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1074\/mcp.R800001-MCP200","article-title":"Urine in clinical proteomics.","volume":"7","author":"Decramer","year":"2008","journal-title":"Mol Cell Proteomics"},{"key":"R32-32-20230601","doi-asserted-by":"crossref","first-page":"F456","DOI":"10.1152\/ajprenal.00095.2007","article-title":"Combined proteomic and metabonomic studies in three genetic forms of the renal Fanconi syndrome","volume":"293","author":"Vilasi","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"R33-32-20230601","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jacc.2008.03.043","article-title":"Application of metabolomics to cardiovascular biomarker and pathway discovery","volume":"52","author":"Lewis","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R35-32-20230601","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1073\/pnas.0611315104","article-title":"Proteomics of specific treatment-related alterations in Fabry disease: A strategy to identify biological abnormalities","volume":"104","author":"Moore","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R36-32-20230601","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S0149-2918(07)80121-4","article-title":"Staging of Fabry disease using renal biopsies","volume":"29","author":"Oliveira","year":"2007","journal-title":"Clin Ther"},{"key":"R37-32-20230601","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1046\/j.1523-1755.2000.00426.x","article-title":"Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1","volume":"58","author":"Ma","year":"2000","journal-title":"Kidney Int"},{"key":"R38-32-20230601","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/S0149-2918(08)80034-3","article-title":"Implications of early renal changes in Fabry disease","volume":"30","author":"Mauer","year":"2008","journal-title":"Clin Ther"},{"key":"R39-32-20230601","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R40-32-20230601","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/08035320600618924","article-title":"Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease","volume":"95","author":"Barbey","year":"2006","journal-title":"Acta Paediatr Suppl"},{"key":"R41-32-20230601","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T","article-title":"Profile of endothelial and leukocyte activation in Fabry patients","volume":"47","author":"DeGraba","year":"2000","journal-title":"Ann Neurol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201002000-00032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:39:10Z","timestamp":1786369150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201002000-00032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.06090809","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}